Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isobutylamido thiazolyl resorcinol plus low-fluence Q-switched Nd:YAG laser for melasma
TCTR20200410010Phase 3Completed
- Sponsor
- Ramathibodi Hospital
- Start
- Oct 2019
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in melasma (2 arms), sponsored by Ramathibodi Hospital. Primary endpoints: Mean relative lightness index, Clinical change in melasma severity and 1 more. Started Oct 2019; status: completed.
02
Conditions
melasma
Beyond the preview
Go deeper on TCTR20200410010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20200410010.